NCT02270021

Brief Summary

The goal of this study is to prevent over screening and over treatment of young women for cervical precancers, which can result in psychological distress and has been associated with future risk of premature deliveries. Current national guidelines recommend that routine screening be performed at less-frequent intervals and that excisional cervical therapies are discouraged in young women. The objectives of this study are to examine physician- and patient-based interventions designed to decrease over screening and over treatment by increasing adherence to US guidelines for women under 30 years.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 24, 2014

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 14, 2014

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 21, 2014

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2018

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2019

Completed
Last Updated

September 25, 2019

Status Verified

September 1, 2019

Enrollment Period

3.8 years

First QC Date

October 14, 2014

Last Update Submit

September 23, 2019

Conditions

Keywords

Pap smearScreeningWomenHuman papillomavirusCervical precancerGuideline adherence

Outcome Measures

Primary Outcomes (1)

  • Rate of Cervical Cancer Screening

    Rate of women 21-29 years who received cervical cytology tests.

    Change from baseline screening rate (3 months prior to intervention) to 15-18 months after start of intervention

Secondary Outcomes (1)

  • Rate of Colposcopy

    Change from baseline colposcopy rate (3 months prior to intervention) to 15-18 months after start of intervention

Study Arms (4)

Provider Mobile Application (ProvAPP)

EXPERIMENTAL

Mobile phone application for providers.

Other: Provider Mobile Application (ProvAPP)

ProvAPP + Patient Educational Tool (Tab)

EXPERIMENTAL

Patient educational tool; plus the Mobile phone application for providers.

Other: ProvAPP + Patient Educational Tool (Tab)

ProvAPP Control Group

NO INTERVENTION

Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.

ProvAPP+Tab Control Group

NO INTERVENTION

Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.

Interventions

Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.

Provider Mobile Application (ProvAPP)

Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices. ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.

ProvAPP + Patient Educational Tool (Tab)

Eligibility Criteria

Age21 Years - 29 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • English or Spanish speaking
  • Women
  • Age 21-29 years
  • History of one or more of the following: abnormal Pap smear, normal Pap smear, no Pap smear, cervical cancer

You may not qualify if:

  • Language other than English or Spanish
  • Male
  • Younger than 21 or older than 29
  • Family PACT provider
  • Not a Planned Parenthood affiliate
  • Located in one of ten identified Southern California study counties
  • Sends cytology/histology specimens to Quest Diagnostics West Hills
  • Clinical care visits occurred to at least 200 women age 21-29 years in fiscal year 2011/2012
  • Has a calculated average cytology interval of less than 30 months (based on last three years)
  • Not a Family PACT provider
  • Planned Parenthood affiliate
  • Not located in one of ten identified Southern California study counties
  • Sends cytology/histology specimens to a lab other than Quest Diagnostics West Hills
  • Clinical care visit occurred to less than 200 women age 21-29
  • Has a calculated average cytology interval of more than 30 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of California, Los Angeles

Los Angeles, California, 90095, United States

Location

University of California, San Francisco

San Francisco, California, 94143, United States

Location

Related Publications (1)

  • Moscicki AB, Chang C, Vangala S, Zhou X, Elashoff DA, Dehlendorf C, Sawaya GF, Kuppermann M, Duron Y, Wyand FL, Navarro SK, Thiel de Bocanegra H. Effect of 2 Interventions on Cervical Cancer Screening Guideline Adherence. Am J Prev Med. 2021 May;60(5):666-673. doi: 10.1016/j.amepre.2020.11.015. Epub 2021 Feb 23.

MeSH Terms

Conditions

Uterine Cervical NeoplasmsUterine Cervical Dysplasia

Interventions

Tablets

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesPrecancerous Conditions

Intervention Hierarchy (Ancestors)

Dosage FormsPharmaceutical Preparations

Study Officials

  • Anna-Barbara Moscicki, MD

    University of California, San Francisco

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Model Details: clinic sites were randomized not subjects
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 14, 2014

First Posted

October 21, 2014

Study Start

July 24, 2014

Primary Completion

April 30, 2018

Study Completion

August 30, 2019

Last Updated

September 25, 2019

Record last verified: 2019-09

Locations